Treatment - Page 14 of 471 Posts on Medivizor
Navigation Menu

Treatment Posts on Medivizor

Evaluating the effectiveness and safety of different platinum-based chemotherapy regimens given after surgery for the treatment of early-stage resected NSCLC.

Evaluating the effectiveness and safety of different platinum-based chemotherapy regimens given after surgery for the treatment of early-stage resected NSCLC.

Posted by on Jan 3, 2023 in Lung cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of different platinum-based chemotherapy regimens given after surgery for the treatment of early-stage resected non-small cell lung cancer (NSCLC). The authors concluded that the combination of cisplatin (Platinol)-vinorelbine (Nevelbine) improved the outcomes of these patients. Also, the...

Read More

Evaluating the effectiveness of different ovarian stimulation protocols for patients with poor ovarian response.

Evaluating the effectiveness of different ovarian stimulation protocols for patients with poor ovarian response.

Posted by on Jan 3, 2023 in Infertility | 0 comments

In a nutshell This study evaluated the effectiveness of different ovarian stimulation protocols for patients with poor ovarian response (POR). The data showed that delayed start gonadotropin-releasing hormone (GnRH) antagonist and microdose GnRH agonist were the two most effective regimens for the treatment of these patients. Some background Many...

Read More

Comparing the effectiveness and safety of combined therapy of atezolizumab with nab-paclitaxel in patients with triple negative breast cancer

Comparing the effectiveness and safety of combined therapy of atezolizumab with nab-paclitaxel in patients with triple negative breast cancer

Posted by on Jan 3, 2023 in Breast cancer | 0 comments

In a nutshell The study compared the effectiveness and safety of atezolizumab (Tecentriq) and nab-paclitaxel (Abraxane) combined therapy with nab-paclitaxel alone in patients with triple-negative breast cancer (TNBC). The study found that combined therapy was more effective than single therapy but it had more serious side effects in these...

Read More

Evaluating the effectiveness of massage therapy for chemotherapy-induced nerve disease

Evaluating the effectiveness of massage therapy for chemotherapy-induced nerve disease

Posted by on Jan 3, 2023 in Breast cancer | 0 comments

In a nutshell The study evaluated the effectiveness of massage therapy for chemotherapy-induced peripheral neuropathy (CIPN) in patients with breast and gastrointestinal (GI) cancer. The main finding of the study was that intensive massage therapy 3 times a week showed promising results in these patients.  Some background There are many...

Read More

Evaluating the effectiveness of massage therapy for chemotherapy-induced nerve disease

Evaluating the effectiveness of massage therapy for chemotherapy-induced nerve disease

Posted by on Jan 3, 2023 in Colorectal cancer | 0 comments

In a nutshell The study evaluated the effectiveness of massage therapy for chemotherapy-induced peripheral neuropathy (CPIN) in patients with breast and gastrointestinal (GI) cancer. The main finding of the study was that intensive massage therapy 3 times a week showed promising results in these patients.  Some background There are many cancer...

Read More

Evaluating treosulfan vs reduced-intensity busulfan conditioning for allogeneic hematopoietic cell transplantation in older patients with acute myeloid leukemia

Evaluating treosulfan vs reduced-intensity busulfan conditioning for allogeneic hematopoietic cell transplantation in older patients with acute myeloid leukemia

Posted by on Dec 31, 2022 in Leukemia | 0 comments

In a nutshell This study aimed to compare the outcomes of allogeneic hematopoietic cell transplant (alloHCT) for older patients with acute myeloid leukemia (AML) using treosulfan (Trecondi) compared to reduced intensity busulfan (Myleran) conditioning.  This study concluded that treosulfan conditioning appears to be more suitable for...

Read More

How effective and safe is rituximab biosimilar HLX01 in patients with moderate to severe rheumatoid arthritis?

How effective and safe is rituximab biosimilar HLX01 in patients with moderate to severe rheumatoid arthritis?

Posted by on Dec 31, 2022 in Rheumatoid Arthritis | 0 comments

In a nutshell This study evaluated the effectiveness and safety of rituximab (Rituxan) biosimilar HLX01 combined with methotrexate (MTX; Trexall) in patients with moderate to severe rheumatoid arthritis (RA) following inadequate responses to MTX. The study showed that HLX01 added to MTX resulted in improvements compared to placebo in these...

Read More

How beneficial is the addition of metformin to insulin therapy for adolescents with type 1 diabetes?

How beneficial is the addition of metformin to insulin therapy for adolescents with type 1 diabetes?

Posted by on Dec 31, 2022 in Diabetes mellitus | 0 comments

In a nutshell This study assessed the effectiveness and safety of adding metformin (Glucophage) to insulin therapy in the treatment of adolescents with type 1 diabetes (T1D). The study showed that the use of metformin in these patients resulted in improved blood glucose control and body mass index (BMI) with an increased risk of...

Read More

Is the use of sodium-glucose cotransporter 2 inhibitors related to the occurrence of eye diseases in patients with type 2 diabetes?

Is the use of sodium-glucose cotransporter 2 inhibitors related to the occurrence of eye diseases in patients with type 2 diabetes?

Posted by on Dec 31, 2022 in Diabetes mellitus | 0 comments

In a nutshell This study investigated the link between sodium-glucose cotransporter 2 inhibitors (SGLT2is) and eye (ocular) diseases in patients with type 2 diabetes (T2D). The data showed that there was no link between the occurrence of eye diseases and SGLT2is in these patients. Some SGLT2is such as ertugliflozin (Steglatro) and empagliflozin...

Read More

Evaluating the long-term outcomes of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutated advanced melanoma.

Evaluating the long-term outcomes of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutated advanced melanoma.

Posted by on Dec 31, 2022 in Melanoma | 0 comments

In a nutshell This study reported the long-term effectiveness and safety of encorafenib (Braftovi) alone or in combination with binimetinib (Mektovi) or vemurafenib (Zelboraf) alone in patients with BRAF-mutated advanced melanoma. The data showed that the encorafenib plus binimetinib combination lead to long-term effectiveness and no new safety...

Read More

Evaluating the effectiveness and safety of zanubrutinib versus bendamustine plus rituximab in untreated patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

Evaluating the effectiveness and safety of zanubrutinib versus bendamustine plus rituximab in untreated patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

Posted by on Dec 31, 2022 in Leukemia | 0 comments

In a nutshell This study investigated the effectiveness and safety of zanubrutinib (Brukinsa) versus bendamustine (Treanda) plus rituximab (Rituxan) in untreated patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The data showed that zanubrutinib significantly improved the survival without cancer worsening versus...

Read More

Evaluating the effectiveness and safety of zanubrutinib versus bendamustine plus rituximab in untreated patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

Evaluating the effectiveness and safety of zanubrutinib versus bendamustine plus rituximab in untreated patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

Posted by on Dec 31, 2022 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the effectiveness and safety of zanubrutinib (Brukinsa) versus bendamustine (Treanda) plus rituximab (Rituxan) in untreated patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The data showed that zanubrutinib significantly improved the survival without cancer worsening versus...

Read More